Human Abuse Potential and Cognitive Effects of Taranabant, a Cannabinoid 1 Receptor Inverse Agonist-Reference-Cited by-同舟云学术

Human Abuse Potential and Cognitive Effects of Taranabant, a Cannabinoid 1 Receptor Inverse Agonist

Published:2012-08 Issue:4 Volume:32 Page:492-502
ISSN:0271-0749
Container-title:Journal of Clinical Psychopharmacology
language:en
Short-container-title:

Author:

Schoedel Kerri A.,Addy Carol,Chakraborty Bijan,Rosko Kim,Dunbar Stephanie,Maes Andrea,Chen Nancy,Stoch Selwyn Aubrey,Wagner John,Chodakewitz Jeff,Sellers Edward M.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Psychiatry and Mental health

Reference45 articles.

1. Endocannabinoid control of food intake and energy balance.;Di Marzo;Nat Neurosci,2005

2. Endocannabinoids in the regulation of appetite and body weight.;Kirkham;Behav Pharmacol,2005

3. Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.;Fong;Int J Obes (Lond),2009

4. . CB1 receptor inverse agonist pharmacotherapy for metabolic disorders.;Fong;Drug Dev Res,2009

5. . The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.;Addy;Cell Metab,2008

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cannabidiol (CBD): Abuse and physical dependence potential;Cannabis Use, Neurobiology, Psychology, and Treatment;2023

2. Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate;Current Medical Research and Opinion;2022-06-03

3. Identification of Optimal Measures of Human Abuse Potential;Journal of Clinical Psychopharmacology;2020-10-21

4. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy;Sleep;2019-10-18

5. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial;Epilepsy & Behavior;2018-11